» Articles » PMID: 29470854

The Cost-Effectiveness of Screening in the Community to Reduce Osteoporotic Fractures in Older Women in the UK: Economic Evaluation of the SCOOP Study

Abstract

The SCOOP study was a two-arm randomized controlled trial conducted in the UK in 12,483 eligible women aged 70 to 85 years. It compared a screening program using the FRAX® risk assessment tool in addition to bone mineral density (BMD) measures versus usual management. The SCOOP study found a reduction in the incidence of hip fractures in the screening arm, but there was no evidence of a reduction in the incidence of all osteoporosis-related fractures. To make decisions about whether to implement any screening program, we should also consider whether the program is likely to be a good use of health care resources, ie, is it cost-effective? The cost per gained quality adjusted life year of screening for fracture risk has not previously been demonstrated in an economic evaluation alongside a clinical trial. We conducted a "within trial" economic analysis alongside the SCOOP study from the perspective of a national health payer, the UK National Health Service (NHS). The main outcome measure in the economic analysis was the cost per quality adjusted life year (QALY) gained over a 5-year time period. We also estimated cost per osteoporosis-related fracture prevented and the cost per hip fracture prevented. The screening arm had an average incremental QALY gain of 0.0237 (95% confidence interval -0.0034 to 0.0508) for the 5-year follow-up. The incremental cost per QALY gained was £2772 compared with the control arm. Cost-effectiveness acceptability curves indicated a 93% probability of the intervention being cost-effective at values of a QALY greater than £20,000. The intervention arm prevented fractures at a cost of £4478 and £7694 per fracture for osteoporosis-related and hip fractures, respectively. The current study demonstrates that a systematic, community-based screening program of fracture risk in older women in the UK represents a highly cost-effective intervention. © 2018 The Authors. Journal of Bone and Mineral Research Published by Wiley Periodicals, Inc.

Citing Articles

Exploring the potential cost-effectiveness and societal burden implications of screening for fracture risk in a UK general radiography setting.

Soreskog E, Lopez B, Bean T, Lewis P, Ashley N, Da Palma Lopes J BMC Musculoskelet Disord. 2025; 26(1):112.

PMID: 39905383 PMC: 11792445. DOI: 10.1186/s12891-024-08202-6.


Excess dietary salt is associated with an altered bone strain index, degraded bone microarchitecture, vertebral fractures, and increased prevalence of osteoporosis in postmenopausal women-A study from a teaching hospital in southern India.

John R, Cherian K, Kapoor N, Paul T Aging Med (Milton). 2024; 7(5):606-613.

PMID: 39507226 PMC: 11535168. DOI: 10.1002/agm2.12360.


Feasibility study of opportunistic osteoporosis screening on chest CT using a multi-feature fusion DCNN model.

Pan J, Lin P, Gong S, Wang Z, Cao R, Lv Y Arch Osteoporos. 2024; 19(1):98.

PMID: 39414670 PMC: 11485148. DOI: 10.1007/s11657-024-01455-7.


Variability in performance of genetic-enhanced DXA-BMD prediction models across diverse ethnic and geographic populations: A risk prediction study.

Liu Y, Meng X, Wu C, Su K, Liu A, Tian Q PLoS Med. 2024; 21(8):e1004451.

PMID: 39213443 PMC: 11404845. DOI: 10.1371/journal.pmed.1004451.


Guidelines for fracture risk assessment and management of osteoporosis in postmenopausal women and men above the age of 50 in Qatar.

Alam F, Alsaed O, Abdulla N, Abdulmomen I, Lutf A, Al Emadi S Arch Osteoporos. 2024; 19(1):34.

PMID: 38698101 PMC: 11065783. DOI: 10.1007/s11657-024-01389-0.


References
1.
Strom O, Borgstrom F, Sen S, Boonen S, Haentjens P, Johnell O . Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries--an economic evaluation based on the fracture intervention trial. Osteoporos Int. 2007; 18(8):1047-61. DOI: 10.1007/s00198-007-0349-5. View

2.
Borgstrom F, Strom O, Coelho J, Johansson H, Oden A, McCloskey E . The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis. Osteoporos Int. 2009; 21(2):339-49. DOI: 10.1007/s00198-009-0971-5. View

3.
Brooks R . EuroQol: the current state of play. Health Policy. 1996; 37(1):53-72. DOI: 10.1016/0168-8510(96)00822-6. View

4.
Kanis J, Johnell O, Oden A, Johansson H, McCloskey E . FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008; 19(4):385-97. PMC: 2267485. DOI: 10.1007/s00198-007-0543-5. View

5.
Borgstrom F, Johnell O, Kanis J, Jonsson B, Rehnberg C . At what hip fracture risk is it cost-effective to treat? International intervention thresholds for the treatment of osteoporosis. Osteoporos Int. 2006; 17(10):1459-71. DOI: 10.1007/s00198-006-0107-0. View